Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00028613 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma
A Phase 1 study of Lymphoma, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
- 1
- Study location
NCT00028613 is a Phase 1 study of Lymphoma that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 2 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00028613, a Phase 1 study of Lymphoma, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances such as radioactive iodine to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibodies in treating patients who have large cell lymphoma that has been previously treated.
Conditions Studied
Interventions
- RADIATION iodine I 131 monoclonal antibody Lym-1
Study Locations (1)
Ohio
- Ireland Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2001-03 |
| Est. Completion | 2001-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00028613
The ClinicalTrials.gov registry entry for NCT00028613 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (100% lower). The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which iodine I 131 monoclonal antibody Lym-1 is the first listed.
NCT00028613 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00028613 about?
NCT00028613 is a clinical study titled "Radiolabeled Monoclonal Antibody in Treating Patients With Previously Treated Large Cell Lymphoma". RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances such as radioactive iodine to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibodies in treating patients who have large cell...
What is the current status of trial NCT00028613?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2001-03. Estimated completion is 2001-10.
What conditions does trial NCT00028613 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00028613?
The interventions under investigation include: iodine I 131 monoclonal antibody Lym-1 (RADIATION).
Who is sponsoring clinical trial NCT00028613?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00028613 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.